Spontaneous adverse event signaling methods: classification and use with health care treatment products.
暂无分享,去创建一个
[1] B Begaud,et al. False-positives in spontaneous reporting: should we worry about them? , 1994, British journal of clinical pharmacology.
[2] G. Faich,et al. The importance of adverse reaction reporting by physicians. Suprofen and the flank pain syndrome. , 1988, JAMA.
[3] D J Graham,et al. Temafloxacin syndrome: review of 95 cases. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] W. Inman. Role of drug-reaction monitoring in the investigation of thrombosis and "the pill". , 1970, British medical bulletin.
[5] I R Edwards,et al. Harmonisation in Pharmacovigilance , 1994, Drug safety.
[6] B. Strom,et al. Screening for Unknown Effects of Newly Marketed Drugs , 1992 .
[7] C. Naranjo,et al. A Bayesian Assessment of Idiosyncratic Adverse Reactions to New Drugs: Guillain‐Barré Syndrome and Zimeldine , 1990, Journal of clinical pharmacology.
[8] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[9] W. Amery. Signal generation from spontaneous adverse event reports , 1999, Pharmacoepidemiology and drug safety.
[10] D. Vervloet,et al. Adverse reactions to drugs , 1998, BMJ.
[11] John A. Clark,et al. Calculation of the Probability of Multiplicities in Two Cell-Occupancy Models: Implications for Spontaneous Reporting Systems , 1999 .
[12] M. D. B. Stephens,et al. The detection of new adverse drug reactions , 1985 .
[13] M. Praus,et al. Alert systems for post-marketing surveillance of adverse drug reactions. , 1993, Statistics in medicine.
[14] G. Faich,et al. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. , 1987, British medical journal.
[15] F. Haramburu,et al. Under-reporting of adverse drug reactions in general practice. , 2003, British journal of clinical pharmacology.
[16] M D Rawlins,et al. Spontaneous reporting of adverse drug reactions. II: Uses. , 1988, British journal of clinical pharmacology.
[17] John A. Clark,et al. Pain and cyanosis associated with α1-proteinase inhibitor , 1992 .
[18] M. Kramer. Assessing Causality of Adverse Drug Reactions: Global Introspection and Its Limitations , 1986 .
[19] M. Lindquist,et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system , 1997, European Journal of Clinical Pharmacology.
[20] S. Shapiro,et al. A study of adverse reaction algorithms in a drug surveillance program , 1985, Clinical pharmacology and therapeutics.
[21] Jaxk Reeves,et al. A statistical signalling model for use in surveillance of adverse drug reaction data , 1998 .
[22] J. Venulet,et al. Methodology for International Drug Monitoring , 1972, Methods of Information in Medicine.
[23] J. Isenberg,et al. Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer. , 1986, The American journal of medicine.
[24] T. Hutchinson,et al. An algorithm for the operational assessment of adverse drug reactions. III. Results of tests among clinicians. , 1979, JAMA.
[25] F. Haramburu,et al. Spontaneous reporting of adverse drug reactions: who reports and what? , 1998, Pharmacoepidemiology and drug safety.
[26] C. Naranjo,et al. The Bayesian Differential Diagnosis of Neutropenia Associated with Antiarrhythmic Agents , 1990, Journal of clinical pharmacology.
[27] L Lasagna,et al. Toward the operational identification of adverse drug reactions , 1977, Clinical pharmacology and therapeutics.
[28] David A. Lane,et al. Causal propositions in clinical research and practice. , 1992, Journal of clinical epidemiology.
[29] L Lasagna,et al. Adverse drug reactions—a matter of opinion , 1976, Clinical pharmacology and therapeutics.
[30] R. Meyboom,et al. Causality classification at pharmacovigilance centres in the european community , 1992 .
[31] I R Edwards,et al. Causal or Casual? , 1997, Drug safety.
[32] Comparing toxicity of drugs use and misuse of spontaneous reporting , 1991 .
[33] A Levine,et al. Signalling Increases in Reporting in International Monitoring of Adverse Reactions to Therapeutic Drugs , 1976, Methods of Information in Medicine.
[34] B. Strom,et al. The epidemiology of the acute flank pain syndrome from suprofen , 1989, Clinical pharmacology and therapeutics.
[35] B. Case,et al. Use of an algorithm to evaluate published reports of adverse drug reactions. , 1991, American journal of hospital pharmacy.
[36] Y. Tsong,et al. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. , 1995, Journal of biopharmaceutical statistics.
[37] J Lellouch,et al. Power and weakness of spontaneous reporting: a probabilistic approach. , 1992, Journal of clinical epidemiology.
[38] D. J. Finney. AN INTERNATIONAL DRUG SAFETY PROGRAM. , 1963, The Journal of new drugs.
[39] Adverse Drug Events and the Freedom of Information Act: An Apple in Eden , 1992, The Annals of pharmacotherapy.
[40] S B Thacker,et al. The Science of Public Health Surveillance , 1989, Journal of public health policy.
[41] Jason C. Hsu. All-pairwise comparisons , 1996 .
[42] David A. Lane,et al. The Bayesian Approach to Causality Assessment: An Introduction , 1986 .
[43] S B Thacker,et al. Public health surveillance in the United States. , 1988, Epidemiologic reviews.
[44] D. J. Finney,et al. The detection of adverse reactions to therapeutic drugs. , 1982, Statistics in medicine.
[45] W. Inman,et al. Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs , 1970, British medical journal.
[46] T. Hutchinson. Standardized Assessment Methods for Adverse Drug Reactions: A Review of Previous Approaches and Their Problems , 1986 .
[47] G M Jacquez,et al. The Analysis of Disease Clusters, Part I: State of the Art , 1996, Infection Control & Hospital Epidemiology.
[48] Guidelines for Good Epidemiology Practices for Drug, Device, and Vaccine Research in the United States , 1996, Pharmacoepidemiology and drug safety.
[49] Paul R. Lehman. A Personal Perspective , 2002 .
[50] B. Flynn,et al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine. , 1992, Journal of the National Cancer Institute.
[51] J. Venulet. Role and place of causality assessment , 1992 .
[52] J W Smith,et al. Studies on the epidemiology of adverse drug reactions. II. An evaluation of penicillin allergy. , 1966, The New England journal of medicine.
[53] Yola Moride,et al. Quality Improvement and Statistical Calculations Made on Spontaneous Reports* , 1994 .
[54] C. Naranjo,et al. Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach , 1994, Clinical pharmacology and therapeutics.
[55] L. Cluff,et al. STUDIES ON THE EPIDEMIOLOGY OF ADVERSE DRUG REACTIONS. I. METHODS OF SURVEILLANCE. , 1964, JAMA.
[56] J. Jones. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. , 1982, Family & community health.
[57] M. Lindquist,et al. Quality criteria for early signals of possible adverse drug reactions , 1990, The Lancet.
[58] Gerald A. Faich,et al. National adverse drug reaction surveillance: 1985. , 1987, JAMA.
[59] A. Bate,et al. A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.
[60] The Food and Drug Administration Algorithm: Special Workshop—Regulatory , 1984, Drug information journal.
[61] A Levine,et al. Pattern Signalling in Health Information Monitoring Systems , 1977, Methods of Information in Medicine.
[62] R. Gaynes,et al. Illness with fatalities in premature infants: association with an intravenous vitamin E preparation, E-Ferol. , 1986, Pediatrics.
[63] S B Thacker,et al. Surveillance in environmental public health: issues, systems, and sources. , 1996, American journal of public health.
[64] G. Faich. US Adverse Drug Reaction Surveillance 1989–1994 , 1996, Pharmacoepidemiology and drug safety.
[65] Thomas P. Gross,et al. Proposed Statistical Methods for Signal Detection of Adverse Medical Device Events , 1998 .
[66] W. Inman,et al. Jaundice after Repeated Exposure to Halothane: An Analysis of Reports to the Committee on Safety of Medicines , 1974, British medical journal.
[68] Patrick C. Waller,et al. Responding to drug safety issues , 1999, Pharmacoepidemiology and drug safety.
[69] D. J. Finney,et al. Statistical Aspects of Monitoring for Dangers in Drug Therapy) , 1971, Methods of Information in Medicine.
[70] T. Hutchinson,et al. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions , 1983, Clinical pharmacology and therapeutics.
[71] C. Bénichou. Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.
[72] L. Knodel,et al. Comparison of three algorithms used to evaluate adverse drug reactions. , 1986, American journal of hospital pharmacy.
[73] A. Carvajal,et al. Aspirin or acetaminophen? A comparison from data collected by the Spanish Drug Monitoring System. , 1996, Journal of clinical epidemiology.
[74] D. H. Lawson. More about Spontaneous Reports of Suspected Adverse Drug Reactions , 1988, Human toxicology.
[75] P. Leuenberger,et al. Judgments of trained observers on adverse drug reactions , 1979, Clinical pharmacology and therapeutics.
[76] R. Meyboom. Causality assessment revisited , 1998, Pharmacoepidemiology and drug safety.
[77] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[78] D M Perrotta,et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. , 1995, The New England journal of medicine.
[79] B. Bégaud,et al. Random models for margins of a 2 x 2 contingency table and application to pharmacovigilance. , 1991, Statistics in medicine.
[80] I. Ralph Edwards,et al. Principles of Signal Detection in Pharmacovigilance , 1997, Drug safety.
[81] C. Naranjo,et al. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events * , 1995, Clinical pharmacology and therapeutics.
[82] J. Venulet. Possible strategies for early recognition of potential drug safety problems. , 1988, Adverse drug reactions and acute poisoning reviews.
[83] C. Naranjo,et al. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. , 1982, British journal of clinical pharmacology.
[84] N. Irey. Adverse drug reactions and death. A review of 827 cases. , 1976, JAMA.
[85] F. Haramburu,et al. Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. , 1996, Journal of clinical epidemiology.
[86] M D Rawlins,et al. Spontaneous reporting of adverse drug reactions. , 1986, The Quarterly journal of medicine.
[87] D. J. Finney. THE DESIGN AND LOGIC OF A MONITOR OF DRUG USE. , 1965, Journal of chronic diseases.
[88] R. Platt,et al. Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. , 1988, The Journal of infectious diseases.
[89] Sachs Rm,et al. An evaluation of spontaneous adverse drug reaction monitoring systems. , 1986 .
[90] L. Waller,et al. The Analysis of Disease Clusters, Part II: Introduction to Techniques , 1996, Infection Control & Hospital Epidemiology.
[91] D. J. Finney,et al. Statistical Logic in the Monitoring of Reactions to Therapeutic Drugs , 1971, Methods of Information in Medicine.
[92] Royall Bw. International aspects of the study of adverse reactions to drugs. , 1971 .
[93] Spontaneous reporting: how many cases are required to trigger a warning? , 1991, British journal of clinical pharmacology.
[94] G. Faich,et al. Adverse-drug-reaction monitoring. , 1986, The New England journal of medicine.
[95] Irey Ns. Teaching monograph. Tissue reactions to drugs. , 1976 .
[96] C S Lao. Application of CUSUM technique and beta-binomial model in monitoring adverse drug reactions. , 1997, Journal of biopharmaceutical statistics.
[97] Chang S. Lao,et al. Statistical Issues Involved in Medical Device Postmarketing Surveillance* , 2000 .
[98] S. Goldman,et al. Limitations and strengths of spontaneous reports data. , 1998, Clinical therapeutics.
[99] D. Bateman,et al. Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom. , 1986, The Quarterly journal of medicine.
[100] M. A. Moussa. Statistical Problems in Monitoring Adverse Drug Reactions , 1978, Methods of Information in Medicine.
[101] D. Greenblatt,et al. A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.
[102] D. Wysowski,et al. Serious Adverse Events in Norplant Users Reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System , 1995, Obstetrics and gynecology.
[103] M. Lifschitz,et al. Suprofen-related nephrotoxicity. A distinct clinical syndrome. , 1987, Annals of internal medicine.
[104] C. Naranjo,et al. The causality assessment of adverse drug reactions using a bayesian approach , 1987 .
[105] L. Cluff,et al. EPIDEMIOLOGICAL STUDIES OF ADVERSE DRUG REACTIONS. , 1965, American journal of public health and the nation's health.
[106] Y. Tsong,et al. False alarm rates of statistical methods used in determining increased frequency of reports on adverse drug reaction. , 1992, Journal of biopharmaceutical statistics.
[107] Algorithms Used in Adverse Drug Event Reports: A Comparative Study , 1997, The Annals of pharmacotherapy.
[108] T. Hutchinson,et al. Assessing methods for causality assessment of suspected adverse drug reactions. , 1989, Journal of clinical epidemiology.
[109] D Wartenberg,et al. Solving the cluster puzzle: clues to follow and pitfalls to avoid. , 1993, Statistics in medicine.
[110] K. Hartmann,et al. Signal Generation in a Non‐EU Country , 1997, Pharmacoepidemiology and drug safety.
[111] M. Kramer. A Bayesian Approach to Assessment of Adverse Drug Reactions: Evaluation of a Case of Fatal Anaphylaxis , 1986 .
[112] Globalization of the Safety Sections of the Periodic Safety Update Report , 1999 .
[113] C. Naranjo. A Clinical Pharmacologic Perspective on the Detection and Assessment of Adverse Drug Reactions , 1986, Drug information journal.
[114] G. Venning. Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? , 1983, British medical journal.
[115] Andrew Bate,et al. From association to alert—a revised approach to international signal analysis , 1999, Pharmacoepidemiology and drug safety.
[116] T. Hutchinson,et al. An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. , 1979, JAMA.
[117] B. Inman. 30 years in postmarketing surveillance. A personal perspective , 1993 .
[118] J. Venulet. Incomplete Information as a Limiting Factor in Causality Assessment of Adverse Drug Reactions and its Practical Consequences , 1986 .
[119] W. Inman,et al. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. , 1968, British medical journal.
[120] F. Haramburu,et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. , 2003, British journal of clinical pharmacology.
[121] J. Drazen,et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. , 1998, JAMA.
[122] D. Lane. A Probabilist's View of Causality Assessment , 1984 .
[123] F. Haramburu,et al. Computerized comparison of six adverse drug reaction assessment procedures , 1986, Clinical pharmacology and therapeutics.
[124] A. Wall,et al. Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .
[125] A. Sampson,et al. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. , 1988, Statistics in medicine.
[126] R. Meyboom,et al. Non-puerperal lactation associated with antidepressant drug use. , 2003, British journal of clinical pharmacology.
[127] M. Lindquist,et al. How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. , 1997, Pharmacology & toxicology.
[128] A R Feinstein,et al. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. , 1979, JAMA.
[129] D. J. Finney,et al. stematic Signalling of Adverse Reactions to Drugs , 1974, Methods of Information in Medicine.
[130] Swyer Gi. Thromboembolic disease and the steroidal content of oral contraceptives. , 1970 .